Eye damage in Graves' disease: can early clues predict who is at risk?
NCT ID NCT07812194
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Researchers at the University of Copenhagen are studying why some people with newly diagnosed Graves' disease develop thyroid eye disease while others do not. The study follows about 430 participants for one year, collecting eye exams, blood and tear samples, and symptom questionnaires. By comparing people who develop eye problems with those who do not, the team aims to build a risk prediction model that could help doctors catch thyroid eye disease earlier.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If researchers identify early warning signs, doctors could monitor and treat people with Graves' disease before thyroid eye disease causes lasting damage.
- What could go wrong
- This observational study cannot prove cause and effect, and the findings may not apply to other populations. Participants receive no experimental treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 430 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Newly diagnosed GD cohort: Potential participants will be identified through approved recruitment reports based on EPIC/Sundhedsplatformen and laboratory data. Reports will identify adults referred to endocrinology outpatient clinics in the Capital Region of Denmark with first-time TRAb \>1.5 IU/L and TSH \<0.01 mU/L, and no previous TRAb \>1.5 IU/L. Participants may also be recruited through public announcements. Moderate-to-severe TED group: Participants will be identified among patients followed at the Endocrinology Outpatient Clinic, Herlev Hospital, and approached during a scheduled visit. Healthy control group: Participants will be recruited through staff advertisements at Herlev and Gentofte Hospital and public announcements.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Newly Diagnosed Graves' Disease (GD) Cohort: * Age 18 years or older * Newly diagnosed GD * Positive TSH receptor antibodies, defined as TRAb \>1.5 IU/L * Biochemical hyperthyroidism, defined as TSH \<0.01 mIU/L * Residence in and/or clinical management within the Capital Region of Denmark, including Hvidovre Hospital, Rigshospitalet, Amager Hospital, Nordsjællands Hospital, Herlev Hospital, and Bispebjerg Hospital. * Ability to provide oral and written informed consent Healthy Control Group: * Age 18 years or older * No known history of GD * No previous positive TRAb measurement * No known thyroid dysfunction requiring antithyroid drug therapy or thyroid hormone replacement therapy * Ability to provide oral and written informed consent Moderate-to-Severe Thyroid Eye Disease (TED) Group: * Age 18 years or older * Diagnosis of moderate-to-severe TED * Followed or treated in a relevant specialized clinical setting * Ability to provide oral and written informed consent Exclusion Criteria: Newly Diagnosed GD Cohort: * Age below 18 years * Previous documented TRAb measurement \>1.5 IU/L prior to the current diagnostic episode * Inability to provide informed consent * Inability to complete the baseline assessment within the predefined study timeframe Healthy Control Group: * Age below 18 years * Known Graves' disease or previous positive TRAb measurement * Known thyroid dysfunction requiring antithyroid drug therapy or thyroid hormone replacement therapy * Inability to provide informed consent Moderate-to-Severe TED Group: * Age below 18 years * Inability to provide informed consent * Inability to complete the planned study assessment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Graves disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Medical Diseases, Endocrinology Unit, Herlev-Gentofte Hospital
Herlev, 2730, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two autoimmune conditions, one child: study probes hidden thyroid trouble
- Why does Graves' disease leave some brains exhausted? scientists hunt for clues in blood and spinal fluid
- Can a pill tame thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can a pill reverse eye bulging in thyroid eye disease?